Comparative Pharmacology
Head-to-head clinical analysis: LARIN FE 1 20 versus LO SIMPESSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN FE 1 20 versus LO SIMPESSE.
LARIN FE 1/20 vs LO SIMPESSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Bile acid sequestrant; binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver, leading to decreased serum LDL cholesterol.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
100 mg orally once daily, with or without food.
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may extend to >40 hours in severe renal impairment (CrCl <30 mL/min).
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Primarily renal, with 70-80% of the dose excreted unchanged in urine; 10-20% via feces through biliary elimination.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive